Date: 2017-12-21
Type of information: Nomination
Compound: chief executive officer
Company: LFB (France)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 21th, 2017, a decree from the President of France was published in Le Journal Officiel appointing Denis Delval CEO of LFB. This decree follows the General Meeting of LFB and the meeting of its Board of Directors, which both took place on December 4th, 2017.Denis Delval is also appointed, CEO of LFB Biomedicaments and President of LFB Biotechnologies as of December 4th, following Christian Béchon and Denis Soubeyran’s departures.
- A graduate of ESSEC and INSEAD business schools with a PhD in Pharmacy, Denis Delval hass held marketing, sales and strategic positions in France, Europe and worldwide and has managed international partnerships within various pharmaceutical groups (Bayer, Fournier Pharma, ALK). In 2006, he was appointed General Manager of ALK France. In 2012, he also became Senior Vice President of the Danish pharmaceutical company specialized in allergy immunotherapy treatments.
Financial terms:
Latest news:
Is general: Yes
